Author:
Kuhlmann Olaf,Hofmann Stefan,Weiss Michael
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference24 articles.
1. Hollingshead LM, Faulds D (1991) Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 42: 690–719.
2. Ames M, Spreafico F (1992) Selected pharmacological characteristics of idarubicin and idarubicinol. Leukemia 6: 70–75.
3. Camaggi CM, Strocchi E, Carisi P, Martoni A, Tononi A, Guaraldi M, Strolin-Benedetti M, Efthymiopoulos C, Pannuti F (1992) Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chemother Pharmacol 30: 307–316.
4. Schleyer E, Kühn S, Rührs H, Unterhalt M, Kaufmann CC, Kern W, Braess J, Sträubel G, Hiddemann W (1996) Oral idarubicin pharmacokinetics-correlation of trough level with idarubicin area under curve. Leukemia 10: 707–712.
5. Fukushima T, Inoue H, Takemura H, Kishi S, Yamauchi T, Inai K, Nakayama T, Imamura S, Urasaki Y, Nakamura T, Ueda T (1998) Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance that is daunorubicin. Leuk Res 22 (7): 625–629.